Skip to main content

REVIEW article

Front. Immunol.
Sec. Nutritional Immunology
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1511229
This article is part of the Research Topic Community Series in Gut Microbiota and Immunity in Health and Disease: Dysbiosis and Eubiosis's Effects on the Human Body, Volume II View all articles

Gut Microbiota Trigger Host Liver Immune Responses That Affect Drug-Metabolising Enzymes

Provisionally accepted
Xiaokang Wang Xiaokang Wang 1*Jiaoyu Rao Jiaoyu Rao 2Peng Qiu Peng Qiu 2Yonggang Zhang Yonggang Zhang 3,4
  • 1 Guangdong Provincial Key Laboratory for Research and Development of Natural Drugs, School of Pharmacy, Guangdong Medical University, Dongguan, China
  • 2 Department of Pharmacy, Shenzhen Longhua District Central Hospital, Shenzhen, China
  • 3 Department of Medical Laboratory, Shenzhen Longhua District Central Hospital, Shenzhen, China
  • 4 Clinical Laboratory Department, Shenzhen Longhua District Central Hospital, Shenzhen, China

The final, formatted version of the article will be published soon.

    There is increasing evidence that the intestinal microbiota plays an integral role in disease pathogenesis and treatment. Specifically, the intestinal microbiota significantly influences the pharmacokinetics and pharmacodynamics of orally administered drugs through direct involvement in drug metabolism and, consequently, drug bioavailability.However, the gut microbiota also exerts immunoregulatory effects on the liver-the organ primarily responsible for drug metabolism-thereby indirectly impacting the body's capacity to metabolise and process drugs. Individual differences in this pathway substantially contribute to the variability in clinical drug treatment outcomes observed between patients. This review examines the impact of liver immune responses, as triggered by the intestinal microbiota, on the activity of drug-metabolising enzymes and discusses the implications for precision medicine.

    Keywords: Gut Microbiota, Liver immune response, Drug-metabolising enzymes, precision medicine, Epigenetic regulation

    Received: 14 Oct 2024; Accepted: 21 Nov 2024.

    Copyright: © 2024 Wang, Rao, Qiu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Xiaokang Wang, Guangdong Provincial Key Laboratory for Research and Development of Natural Drugs, School of Pharmacy, Guangdong Medical University, Dongguan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.